Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, England.
Antibody
SARS-CoV-2
School
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
08
07
2021
revised:
09
09
2021
accepted:
15
09
2021
entrez:
5
10
2021
pubmed:
6
10
2021
medline:
6
10
2021
Statut:
ppublish
Résumé
Prospective, longitudinal SARS-CoV-2 sero-surveillance in schools across England was initiated after the first national lockdown, allowing comparison of child and adult antibody responses over time. Prospective active serological surveillance in 46 primary schools in England tested for SARS-CoV-2 antibodies during June, July and December 2020. Samples were tested for nucleocapsid (N) and receptor binding domain (RBD) antibodies, to estimate antibody persistence at least 6 months after infection, and for the correlation of N, RBD and live virus neutralising activity. In June 2020, 1,344 staff and 835 students were tested. Overall, 11.5% (95%CI: 9.4-13.9) and 11.3% (95%CI: 9.2-13.6; The immune response in children following SARS-CoV-2 infection was robust and sustained (>6 months) but further work is required to understand the extent to which this protects against reinfection.
Sections du résumé
BACKGROUND
BACKGROUND
Prospective, longitudinal SARS-CoV-2 sero-surveillance in schools across England was initiated after the first national lockdown, allowing comparison of child and adult antibody responses over time.
METHODS
METHODS
Prospective active serological surveillance in 46 primary schools in England tested for SARS-CoV-2 antibodies during June, July and December 2020. Samples were tested for nucleocapsid (N) and receptor binding domain (RBD) antibodies, to estimate antibody persistence at least 6 months after infection, and for the correlation of N, RBD and live virus neutralising activity.
FINDINGS
RESULTS
In June 2020, 1,344 staff and 835 students were tested. Overall, 11.5% (95%CI: 9.4-13.9) and 11.3% (95%CI: 9.2-13.6;
INTERPRETATION
CONCLUSIONS
The immune response in children following SARS-CoV-2 infection was robust and sustained (>6 months) but further work is required to understand the extent to which this protects against reinfection.
Identifiants
pubmed: 34608455
doi: 10.1016/j.eclinm.2021.101150
pii: S2589-5370(21)00430-2
pmc: PMC8481203
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101150Informations de copyright
Crown Copyright © 2021 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
MR reports that The Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. All other authors have nothing to declare.
Références
JAMA Netw Open. 2021 Mar 1;4(3):e214302
pubmed: 33749770
EMBO J. 2021 Mar 1;40(5):e106228
pubmed: 33258165
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Lancet Infect Dis. 2021 Jun;21(6):e143
pubmed: 33220726
Nat Immunol. 2021 Jan;22(1):25-31
pubmed: 33154590
Clin Microbiol Infect. 2021 Jan 20;:
pubmed: 33482352
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32796155
Pediatrics. 2020 Nov;146(5):
pubmed: 32887791
J Infect. 2021 May;82(5):162-169
pubmed: 33766553
Lancet Child Adolesc Health. 2021 Jun;5(6):417-427
pubmed: 33740430
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Nat Immunol. 2021 May;22(5):620-626
pubmed: 33674800
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Lancet Reg Health Eur. 2021 Apr;3:100038
pubmed: 33870248
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
EClinicalMedicine. 2020 Nov;28:100597
pubmed: 33173854
Pediatr Infect Dis J. 2020 May;39(5):355-368
pubmed: 32310621
Sci Transl Med. 2020 Oct 7;12(564):
pubmed: 32958614